Member Info for Peter10

Any views on this ? Most business to business settle and you sense that Tunisia may want this to go away following the ministerial change

Hanging on in there with a few but cant disclose how much I have lost on this share.

Anyway if any connected person is reading this ....

Will email again and ask what is happening withthe Erasmus/Glioblastoma work that shouldnt be costing TCF a bean

I asked a few times years back about monetising SFX/01 as an OTC supplement but at the time that was a No on the basis it would detract from drug price ... what about now ?

Other quick observation is solid continuity on C - team ...either they believe they are onto a winner OR being remunerated well OR both

Can you give someone a nudge on letting us know what's happening on the Erasmus trials . It was scheduled to start and would be very newsworthy . Flip side of course is it could be very disappointing

I think the Erasmus tie up has been covered but it's been quiet for a while so thought I would check for something to relieve my gloom. So the trials that are mentioned should be newsworthy when they start and that may be soon

These trials don't cost a bean to tcf as far as I can revall

Im also very jaded on this one but its positive news nonetheless. I was trying to check if there was anything on SFX01/Erasmus and below came up on AI. Excuse the formatting

There is definitely news specifically for TheraCryf’s (formerly Evgen Pharma) SFX-01 at Erasmus MC, though it has been flying slightly under the radar because of the company's recent rebranding to TheraCryf (TCF).The "SFX-01 in Glioblastoma" project is very much active. Here is the breakdown of the progress from the last 6 months, including the "window of opportunity" study you likely have in mind.1. Shift to "Patient Dosing" Phase (Early 2026)The most significant update from late 2025/early 2026 is that the project has moved from the laboratory bench to the clinic.Status: In-vitro (test tube) and in-vivo (animal model) work at Erasmus MC is now complete.Next Milestone: The first patients are scheduled to be dosed in early 2026 (H1 2026).The Study Design: This is a "Phase 0" or "Window of Opportunity" trial. Patients will receive SFX-01 for a short period before their scheduled brain surgery. Surgeons will then analyze the removed tumor tissue to see exactly how much of the drug crossed the blood-brain barrier and how it affected the cancer cells in a real human environment.2. Encouraging Pre-clinical ResultsIn the final months of 2025, Dr. Marjolein Geurts (the lead neuro-oncologist at Erasmus MC) reported that the preliminary laboratory work on patient-derived tissue from the Netherlands was successful.The drug showed "striking" biological activity, consistent with earlier studies in Italy and New Zealand.Specifically, SFX-01 appears to target STAT3 and Nrf2 pathways, which are critical because they often help glioblastoma cells resist standard radiotherapy.3. Funding & Financial BackingKWF Grant: The study remains fully funded by a €1.1 million grant from the KWF Dutch Cancer Society. This is "non-dilutive" funding, meaning the research is progressing without TheraCryf having to spend its own limited cash reserves.Manufacturing: In June 2025, TheraCryf confirmed that they have secured the manufacturing capacity (via Pharmaron UK) to supply the specific enteric-coated tablets needed for the Erasmus patients.4. Why it wasn't in the "Main" newsIf you were looking for "Evgen Pharma," you might have missed these updates because:Rebranding: The company is now TheraCryf PLC (Ticker: TCF).Priority Shift: Their internal "priority" has shifted to an addiction drug called Ox-1. They now categorize SFX-01 as a "legacy asset" or "secondary lever" because it is being managed and funded externally by Erasmus MC.Summary Table: SFX-01 RoadmapPhaseTimingStatusIn-vitro/In-vivo Lab Work2024 – Late 2025Complete (Positive results)Clinical Trial PreparationsQ4 2025Underway (Regulatory/Ethics)First Patient Dosed (Phase 0)H1 2026Upcoming / ImminentInitial Clinical Data ReadoutLate 2026Projected

Nice to see someone not selling ... Looks to be from the construction family

Https://youtu.be/NoL7kQtmrOw?si=YX5n_v5G1PSfDk-6

Maybe that will work but believe you may need to change the http thingy

Rhonda Patrick just released a short video talk on the benefits of sulf ...it's on you tube and easily found but linking it is beyond me. Amazingly good stuff to get in your diet and there are some decent supplements out there ...I take avmacol and prostophane .

Got to ask the board again why they don't get sfx01 out there ... Seems to be sitting on their shelf at the moment aside from the 2 university studies

As a longish term holder but a non poster, I feel the news flow is more positive than for some time . Sold about 75 % of holding at a big loss but looking at adding as funds free up . I am a terrible optimist

I believe the work today has been free but they said they are putting a $ deal together for the continuation so hopefully endorsement , validation and cash

Just had an email with nanoco on the list of speakers . First time I've ever seen them listed on these so at least they are getting out there.

Was it recorded ? Any Q and A?

Bought a few off the Charles Archer article. Looks a decent bet and bought a few

Good to read thanks

Thanks. How do I get in with the code ... Can't see it on the mello website

2 very enthused scientists for a change. Not a Huw , Tony or Alistair in sight. Sounds positive

Duh !!!

Investor Meet Company

Orexin meeting currently on ...will be recorded

Hi DS, I did ask that question (without the stalicla angle) at the last presentation a few months back . He said no back then, mainly due to low supplement pricing as I recall but will check back. I would buy it for sure and do take a couple of sulfiraphabe supplements anyway

A random and probably fanciful thought would be to have a couple more patient stories . I recall something a way back and it really shines a light on the science when you get a human angle . Fingers crossed for the buds of May.